Neurosciences, Clinical Effectiveness and Public Health Research Group, Universidad Cientifica del Sur, Lima, Peru.
Clinical and Health Efficacy Network, REDECS, Lima, Peru.
Epilepsia. 2021 Apr;62(4):984-996. doi: 10.1111/epi.16850. Epub 2021 Mar 2.
This study was undertaken to perform an updated systematic review and meta-analysis to estimate the pooled prevalence and incidence of epilepsy in Latin America and the Caribbean (LAC), describing trends over time, and exploring potential clinical and epidemiological factors explaining the heterogeneity in the region.
Observational studies assessing the incidence or prevalence of epilepsy in LAC countries up to March 2020 were systematically reviewed according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Meta-analyses and cumulative analyses were performed using random-effects models. We assessed between-study heterogeneity with sensitivity, subgroup, and meta-regression analyses. Moreover, the quality of the included studies and the certainty of evidence were evaluated using the GRADE (grading of recommendation, assessment, development, and evaluation) approach.
Overall, 40 studies (from 42 records) were included, 37 for prevalence analyses and six for incidence (312 387 inhabitants; 410 178 person-years). The lifetime prevalence was 14.09 per 1000 inhabitants (95% confidence interval [CI] = 11.72-16.67), for active epilepsy prevalence was 9.06 per 1000 individuals (95% CI = 6.94-11.44), and the incidence rate was 1.11 per 1000 person-years (95% CI = .65-1.70). These high estimates have been constant in the region since 1990. However, substantial statistical heterogeneity between studies and publication bias were found. The overall certainty of evidence was low. Methodological aspects (sample size) and countries' epidemiological characteristics such as access to sanitation services and child and adult mortality rates explained the high heterogeneity. Finally, the prevalence of epilepsy associated with neurocysticercosis (NCC) in the general population was high, and the proportion of NCC diagnosis among people living with epilepsy was 17.37%.
The epilepsy prevalence and incidence in LAC are higher than worldwide estimates, being constant since 1990 and strongly influenced by NCC. We identified high between-study heterogeneity and significant methodological limitations (e.g., heterogeneous definitions, lack of longitudinal studies). The region needs upgraded research using standardized definitions and diagnostic methods, and urgent action against preventable causes.
本研究旨在进行更新的系统评价和荟萃分析,以估计拉丁美洲和加勒比地区(LAC)的癫痫患病率和发病率,描述随时间的变化趋势,并探讨可能的临床和流行病学因素,解释该地区的异质性。
根据 PRISMA(系统评价和荟萃分析的首选报告项目)指南,系统地回顾了评估 LAC 国家癫痫发病率或患病率的观察性研究。使用随机效应模型进行荟萃分析和累积分析。我们使用敏感性分析、亚组分析和荟萃回归分析评估了研究之间的异质性。此外,还使用 GRADE(推荐、评估、发展和评估)方法评估了纳入研究的质量和证据的确定性。
总体而言,纳入了 40 项研究(来自 42 条记录),其中 37 项用于患病率分析,6 项用于发病率分析(312 387 名居民;410 178 人年)。终生患病率为每 1000 名居民 14.09 例(95%置信区间[CI] = 11.72-16.67),活动性癫痫患病率为每 1000 人 9.06 例(95% CI = 6.94-11.44),发病率为每 1000 人年 1.11 例(95% CI =.65-1.70)。自 1990 年以来,这些高估计值在该地区一直保持不变。然而,研究之间存在显著的统计学异质性和发表偏倚。总体证据确定性水平较低。方法学方面(样本量)和国家的流行病学特征,如获得卫生服务以及儿童和成人死亡率,解释了高异质性。最后,普通人群中与神经囊虫病(NCC)相关的癫痫患病率较高,而在癫痫患者中 NCC 的诊断比例为 17.37%。
LAC 的癫痫患病率和发病率高于全球估计值,自 1990 年以来一直保持不变,并且受 NCC 的影响很大。我们发现研究之间存在高度异质性和显著的方法学局限性(例如,定义不统一,缺乏纵向研究)。该地区需要使用标准化定义和诊断方法进行升级研究,并采取紧急行动预防可预防的原因。